Compared to daily oral pre-exposure prophylaxis (PrEP), lenacapavir reduces the number of new HIV infections by many more; causes slightly fewer serious unwanted effects; and results in little to no ...
Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current methods. Many people take daily oral ...
A recent study published in JAMA Network Open evaluated the cost-effectiveness of monoclonal antibodies (mAbs) as pre-exposure prophylaxis (PrEP) for coronavirus disease 2019 (COVID-19). Study: Health ...
A new HIV antiretroviral shows promise as a long-acting, oral prophylactic agent, according to a new study by Izzat Raheem, Tracy Diamond and colleagues from Merck & Co., Inc., Rahway, NJ, USA, ...
HIV pre-exposure prophylaxis (PrEP) is an effective and safe intervention for individuals with behaviors that are considered high risk for acquiring HIV infection. Despite the success of this ...
Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...
Among individuals using HIV pre-exposure prophylaxis (HIV PrEP), doxycycline post-exposure prophylaxis (doxyPEP) was associated with a substantial decline in chlamydia and syphilis incidence.
Before Ciarra Covin was diagnosed with HIV in 2008, medications called PrEP (pre-exposure prophylaxis) that prevent HIV infection didn’t exist. As a college student in rural Georgia, Covin found out ...
About The Study: This decision analytic model showed that within the context of a high SARS-CoV-2 probability, monoclonal antibodies pre-exposure prophylaxis (mAbs PrEP) provision was cost-saving when ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results